header logo image


Page 957«..1020..956957958959..970980..»

ELSI Program – National Human Genome Research Institute

August 1st, 2017 7:49 pm

ELSI Research ProgramThe Ethical, Legal and Social Implications (ELSI) Research Program

ELSI Research Program Overview

The National Human Genome Research Institute's (NHGRI) Ethical, Legal and Social Implications (ELSI) Research Program was established in 1990 as an integral part of the Human Genome Project (HGP) to foster basic and applied research on the ethical, legal and social implications of genetic and genomic research for individuals, families and communities. The ELSI Research Program funds and manages studies, and supports workshops, research consortia and policy conferences related to these topics.

An article describing the ELSI Research Program in greater detail can be found here:The Ethical, Legal and Social Implications Program of the National Human Genome Research Institute: Reflections on an Ongoing Experiment

The NHGRI Division of Genomics and Society has identified the following three research domains to be considered for support by the Ethical, Legal and Social Implications (ELSI) Research Program. The domains are overlapping, and it is anticipated that many research projects will address issues that cut across domains. A more detailed discussion of these domains and a list of examples of possible research topics is available atELSI Research Domains.

Genetic and Genomic Research. These projects may investigate and address the ethical, legal, social, and policy issues that arise in connection with the design and conduct of genetic and genomic research.

Genetic and Genomic Health Care. These projects may investigate and address the ethical, legal, social, and policy issues that arise in connection with the translation of genetic and genomic research into clinical medicine and health care in a variety of healthcare settings.

Broader Legal, Policy and Societal Issues. These projects may investigate and address a range of broader ethical, legal, policy and societal issues raised by the use of genetic and genomic technologies and information in research, clinical or non-medical settings.

Top of page

Coming soon

The NHGRI ELSI Program accepts Conference Grant (R13) applications. For specific instructions for preparing a conference grant application, see:

The ELSI program participates in a number of training and career development funding opportunities.

The Fogarty International Center's international bioethics training programs[fic.nih.gov] support education and research training to develop ethics expertise in low- and middle-income countries (LMICs). The programs complement other global health research and research training programs in the mission areas of NIH Institutes and Centers.

PA-16-288[grants.nih.gov]:Research Supplements to Promote Diversity in Health-Related Research (Admin Supp)Expiration Date: September 30, 2019

PA-16-288[grants.nih.gov].Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp)Expiration Date: September 30, 2019

Top of page

Top of page

In the Fall of 2003, the NHGRI in collaboration with U.S. Department of Energy (DOE) and the National Institute of Child Health and Human Development (NICHD) launched a new initiative to create interdisciplinary Centers of Excellence in ELSI Research (CEER). The CEERs are designed to bring investigators from multiple disciplines together to work in innovative ways to address important new, or particularly persistent, ethical, legal, and social issues related to advances in genetics and genomics. In addition, the centers will support the growth of the next generation of researchers on the ethical, legal and social implications of genomic research. Special efforts will be made to recruit potential researchers from under-represented groups.

NIH funds new studies on ethical, legal and social impact of genomic information NewMay 17, 2016

For more information about the CEER's program, see: Centers of Excellence in ELSI Research (CEER).

Top of page

Joy Boyer, B.A.E-mail: boyerj@exhange.nih.gov

Dave Kaufman, Ph.D.E-mail: dave.kaufman@nih.gov

Nicole Lockhart, Ph.D.E-mail: lockhani@mail.nih.gov

Jean McEwen, J.D., Ph.D.E-mail: mcewenj@mail.nih.gov

Erin CurreyE-mail:Erin.currey@nih.gov

Margaret GinozaE-mail:margaret.ginoza@nih.gov

Tasha StewartE-mail: Tasha.stewart@nih.gov

AddressThe Ethical, Legal and Social Implications Research ProgramNational Human Genome Research InstituteNational Institutes of Health5635 Fishers LaneSuite 4076, MSC 9305Bethesda, MD 20892-9305

Phone: (301) 402-4997Fax: (301) 402-1950E-mail: elsi@nhgri.nih.gov

Top of page

Last Updated: July 10, 2017

Continued here:
ELSI Program - National Human Genome Research Institute

Read More...

How Powerful is CRISPR? – Newswise (press release)

August 1st, 2017 7:49 pm

Newswise "Good morning, doctor, I am here for my gene editing appointment. In the future, could this be a greeting heard in physician offices around the world? With the introduction of CRISPR technology, genetic material can now be more easily and precisely edited, even creating changes that can subsequently be inherited by offspring.

CRISPR stands for clustered regularly interspaced short palindromic repeats, and is often used as shorthand for the CRISPR-associated protein 9 (Cas9) technology that in the lab can remove and replace specific sequences of DNA. Scientists now expect that it will be harnessed to treat and or possibly cure debilitating diseases such as sickle cell anemia, Duchenne muscular dystrophy, Huntingtons disease, HIV, and cancers. Preclinical studies are underway to assess the safety of CRISPR-Cas9 and its ability to discriminate healthy from non-healthy cells.

Jennifer Doudna, PhD, a geneticist and a co-creator along with Emmanuelle Carpenter, PhD, of the CRISPR-Cas9 technology, delivered the Wallace H. Coulter Lectureship Award plenary on Sunday with her talk, CRISPR Biology, Technology & Ethics: The Future of Genome Engineering.

A key leader in the field, Doudna detailed her laboratorys innovative findings that she has collectively referred to as a molecular scalpel for genomes. She intrigued the audience by reviewing the intricate bacterial CRISPR adaptive immune system and how her lab harnessed its power to edit genes. She also delved into CRISPRs potential applications, current limitations, and ethical concerns.

Work is ongoing aimed at making CRISPR more amenable to fighting disease.

Doudna explained how her current research is refining CRISPRCas9 to improve its efficiency and prevent off-target mutations. Her laboratory has developed a CRISPRCas9 targeted gene knockdown method with enhanced efficiency. This method employs techniques such as single-particle electron microscopy to delineate the molecular mechanisms underlying the highly diverse CRISPR-Cas networks.

Several researchers already are using CRSPR to edit genes. Gene editing research in animal models involving mice and monkeys, in human embryos, and in HIV-infected human cells show promise. For example, in 2016 Lu You, MD, and colleagues at Sichuan University in Chengdu became the first group in the world to inject CRISPRCas9 modified T cells into patients with non-small cell lung cancer. The technology also is being used to speed pharmaceutical research and identify targeted therapies for somatic and heritable diseases.

A scan of ClinicalTrials.gov produces more than 10 clinical trials focused on examining the efficacy of CRISPR-Cas9 in diseases as varied as human papillomavirus-related malignant neoplasm (NCT03057912), HIV-1 (NCT03164135), sickle cell disease (NCT03167450), and prostate cancer (NCT02867345). The majority of these trials have not commenced patient recruitment.

What social and ethical frameworks should we use to consider research using CRISPR-Cas9? Be sure to attend the Wednesday afternoon symposium, Ethics in Laboratory Medicine, where Seema Mohapatra, JD, MPH will present Legal and Ethical Issues with Mitochondrial Replacement and CRISPR-Cas9. She will discuss the applications of technologies such as developing so-called designer babies, and the controversy surrounding what impact CRISPR gene editing will have on modern eugenics. Mohapatra has written in law journals about the need to examine such technology through the lens of reproductive justice and disability justice to ensure that all voices are heard and all populations can benefit from such powerful scientific discoveries.

CRISPR-Cas9 and mitochondrial replacement technologies are here, and the widespread opportunity for their clinical use in humans is imminent. Laboratorians, what roles will you play in ensuring the ethnical use of these powerful technologies?

See the rest here:
How Powerful is CRISPR? - Newswise (press release)

Read More...

The Alliance for Regenerative Medicine Issues Statement in Response to Reports of the First Use of Gene Editing … – Benzinga

August 1st, 2017 7:49 pm

WASHINGTON, DC--(Marketwired - Jul 27, 2017) - The Alliance for Regenerative Medicine (ARM) has issued the following statement in response to the news that a research team from the Oregon Health and Science University has, for the first time in the United States, utilized gene editing technology to modify human embryos:

ARM continues to monitor the latest developments in gene-editing technologies, given their enormous medical potential. We reiterate our encouragement and support of the use of these technologies in somatic (non-reproductive) human cells to durably treat and potentially cure human diseases. Patients will benefit more immediately from resources being directed towards somatic applications of the technologies at this time, as most genetic diseases manifest in and can be treated in somatic, not germline, cells. In addition, many unresolved safety, ethical and legal issues remain with human germline engineering approaches.

ARM continues to support the National Academies of Sciences, Engineering and Medicine (NASEM), which noted in its February 2017 report, "heritable germline editing is not ready to be tried in humans."

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 265 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Continued here:
The Alliance for Regenerative Medicine Issues Statement in Response to Reports of the First Use of Gene Editing ... - Benzinga

Read More...

Will Healthcare Inequality Cause Genetic Diseases to Disproportionately Impact the Poor? – Gizmodo

August 1st, 2017 7:49 pm

Artwork via Angelica Alzona/Gizmodo

Today in America, if you are poor, you are also more likely to suffer from poor health. Low socioeconomic statusand the lack of access to healthcare that often accompanies ithas been tied to mental illness, obesity, heart disease and diabetes, to name just a few.

Imagine now, that in the future, being poor also meant you were more likely than others to suffer from major genetic disorders like cystic fibrosis, TaySachs disease, and muscular dystrophy. That is a future, some experts fear, that may not be all that far off.

Most genetic diseases are non-discriminating, blind to either race or class. But for some parents, prenatal genetic testing has turned what was once fate into choice. There are tests that can screen for hundreds of disorders, including rare ones like Huntingtons disease and 1p36 deletion syndrome. Should a prenatal diagnosis bring news of a genetic disease, parents can either arm themselves with information on how best to prepare, or make the difficult decision to terminate the pregnancy. That is, if they can pay for it. Without insurance, the costs of a single prenatal test can range from a few hundred dollars up to $2,000.

And genome editing, should laws ever be changed to allow for legally editing a human embryo in the United States, could also be a far-out future factor. Its difficult to imagine how much genetically engineering an embryo might cost, but its a safe bet that it wont be cheap.

Reproductive technology is technology that belongs to certain classes, Laura Hercher, a genetic counselor and professor at Sarah Lawrence College, told Gizmodo. Restricting access to prenatal testing threatens to turn existing inequalities in our society into something biological and permanent.

Hercher raised this point earlier this month in pages of Genome magazine, in a piece provocatively titled, The Ghettoization of Genetic Disease. Within the genetics community, it caused quite a stir. It wasnt that no one had ever considered the idea. But for a community of geneticists and genetic counsellors focused on how to help curb the impact of devastating diseases, it was a difficult thing to see articulated in writing.

Prenatal testing is a miraculous technology that has drastically altered the course of a womans pregnancy since it was first developed in the 1960s. The more recent advent of noninvasive prenatal tests made the procedure even less risky and more widely available. Today, most women are offered screenings for diseases like Down syndrome that result from an abnormal presence of chromosomes, and targeted testing of the parents can hunt for inherited disease traits like Huntingtons at risk of being passed on to a child, as well.

But there is a dark side to this miracle of modern medicine, which is that choice is exclusive to those who can afford and access it.

This is one of those aspects of prenatal testing that we dont want to talk about, Megan Allyse, who studies reproductive ethics at the Mayo Clinic, told Gizmodo. Theres a wide variety of reasons people might not get access to reproductive technologies. But what is unavoidable is that you are more likely to have access if you are socio-economically well-off.

The scenario Hercher imagines is this: Say you dont have insurance, or have insurance that does not cover the roster of prenatal tests that OB/GYNs commonly recommend. You also cannot afford the tests out-of-pocket, and your baby is born with a genetic disease. This scenario plays out over and over again among people who cannot afford testing, while at the same time many of those who can afford the test for that disease and test positive choose to terminate a pregnancy. Over time, Hercher predicts, that disease would become more prevalent in those communities that could not afford the tests.

Whether this hypothetical scenario will play out in the real world isnt totally clear, in part because there are many variables besides socioeconomic status at work. Maybe you live in a state where abortions are more difficult to access or against local norms, influencing your decision to undergo prenatal testing. Perhaps you oppose abortion for cultural or religious reasons. And there isnt data for on individuals who refuse prenatal testing altogether, even if they could afford it. Somewhere around 70 percent of women opt-in to some form of prenatal testing, but those numbers vary wildly by region, jumping up to about 90 percent on the coasts and dropping significantly in the midwest.

At this point, all researchers can really do is speculate about future disparities in genetic disease. For example, a 2012 meta-analysis published in Prenatal Diagnosis found that across the country, the mean termination rate for Down syndrome was 67 percent, meaning that a significant number of people who undergo prenatal testing and wind up testing positive for Down syndrome choose to end the pregnancy. Of course, not every parent who learns their future child will have Down syndrome wants to terminate the pregnancy. Its is a complex, personal choice. But access to prenatal testing also allows a parent to better plan for their childs future needs.

Some geneticists already see evidence of an accessibility gap in their own clinical practices.

Certainly we know that access to care varies, Massachusetts General medical geneticist Brian Skotko told Gizmodo. His own work has studied the demographic breakdown of Down syndrome, and has found a clear racial pattern in both Down syndrome births and pregnancy terminations.

In Massachusetts, were seeing more Hispanic and black mothers with [babies with Down syndrome], he said, and what weve learned from their stories is either they dont have access to testing or that if they did get tested, they had strong religious beliefs.

As access to prenatal testing increases, Skotko said, it is likely we will see a drastic reduction in genetic diseases. In the next five years, as tests get better and better, the global market for them is expected to balloon by 25 percent to over $10 billion. We can look to historical evidence, Skotko said. As more people get access to prenatal tests, there will be an increase in number of selective terminations.

Access to prenatal testing isnt the only thing that could lead to Herchers fear becoming a reality, either. Abortion access has become increasingly difficult in some parts of the country, with states like Texas stripping funding for clinics and placing more restrictions on the conditions under which they can take place. In vitro fertilization could one day also contribute, allowing those who can afford the tens of thousands of dollars to undergo IVF to select the most genetically-desirable eggs for implantation.

In her new book, Whittier Law School professor Judith Daar makes a terrifying prediction: that unequal access to IVF may wind up bringing about a new eugenics.

The growth and success of reproductive technologies, accounting for three out of every one hundred babies born in the United States today, have prompted lawmakers to introduce and occasionally pass legislation that expressly or indirectly limits access to [assisted reproductive technologies] by certain individuals, she writes. These formal legal barriers, combined with individual and practice-wide physician conduct, coalesce to suppress access to assisted conception for those who have historically experienced a devaluation of their reproductive worth.

Daar points out that while in the 1942 case Skinner v. Oklahoma, the Supreme Court affirmed that procreation is a right, striking down the states compulsory sterilization of certain criminals, the ruling only weighs in on procreating naturally. The court has yet to rule on anything that might also equalize access to technologies that could help with conception, or to ensure that a child conceived is healthy.

Whats missing in the conversation is how we adopt all of these technologies to a society that considers well-being for all, Eleonore Pauwels, a bioethicist at the Wilson Center, told Gizmodo. There is already an access problem. But what about when were editing out diseases? Who will pay for CRISPR? We are looking at much more disruption in the future.

The only real way to prevent genetic diseases from becoming diseases of poverty, said Josephine Johnston, a bioethicist at The Hastings Institute, is to make sure everyone has access to the same services. While the costs of todays tests may one day be affordable for more people, there will inevitably also be newer, more expensive technologies that create the same issues in the future. Thus is the cycle of healthcares disparity of accessthere are always people for whom treatment is not equal to the rest.

People have to have access to healthcare services, and [genetic testing] needs to be part of what those services include, she told Gizmodo. If you dont have access to testing and termination servicesor support if you continue the pregnancyyou dont really have a choice about what to do. Its not a choice if youre backed into a corner.

The inequality threat that prenatal testing, IVF and germline editing present, is of course a version of the same inequality that has always existed. If you are poor, there is a good chance your access to healthcare is not as good as someone who has more money.

But as these technologies grow in power and expense, the gulf of that inequality widens. Genetic disease has always been our shared vulnerability, Hercher wrote in Genome. When one part of society can opt out of risk, will they continue to feel the same obligation to provide support and resources to those who remain vulnerable, especially if at least some of them have deliberately chosen to accept the risk?

Hercher presents what is really a common vision of dystopia: a future of genetic haves and have-nots in which inequality becomes encoded in our basic biology. But arriving at that future does not require genetic engineering or some other as-yet-unknown technology. All it requires is that we keep doing what we are already doing, living in a world in which access to necessary healthcare is often a luxury off-limits to the poor.

Editors Note: A quotation from Brian Skotko has been changed to reflect the preferred language used to refer to people with Down syndrome.

See original here:
Will Healthcare Inequality Cause Genetic Diseases to Disproportionately Impact the Poor? - Gizmodo

Read More...

"Rewriting" yeast genomes: Paving the way to create human DNA from scratch – MIMS General News (Hong Kong) (registration) (blog)

August 1st, 2017 7:49 pm

Jeff Boeke, director of the Institute for Systems Genetic s at New York University School of Medicine, has been working with his team on "rewriting" the yeast genome or, creating new yeast DNA codes to be transcripted into yeast cells.

The controversial project aims to supplement Genome Project-write or GP-write, which focuses on creating new genomes for humans and other animals that began in June 2016 by Boeke, and a group of other scientists, including the controversial geneticist from Harvard University, George Church.

The concept is that synthetic human genomes created, can be inserted into ordinary human cells whose natural DNA has been removed. This should, theoretically, then allow the scientists to match genetic sequences to their relevant traits, disease processes, and physiological functions.

A secret initial meeting to discuss GP-write was conducted in May this year and many experts are concerned about the ethical, legal and social issues, as well as skeptical as to whether the team will be able to fully synthesise human DNA.

The team hopes that this would be a stepping stone for GP-write and reveal basic, hidden rules that govern the structure and functioning of genomes and also possibly reveal new and useful characteristics that can yield new vaccines, biofuels or be part of the drug-manufacturing process in pharmaceutical factories.

"[Cell lines] have been cultured in dishes in labs for decades. But you can't engineer the genomes the tools for doing that are quite crude, relatively speaking," he says. A synthetic cell that lacked unnecessary genetic material could, consistently produce useful drugs to treat disease.

To design a stretch of DNA, the team begins with a stretch of normal, nature-made DNA and uploads that sequence onto a computer. Then, through an internally designed algorithm, specific changes are made to the sequence.

This altered sequence then becomes a blueprint and is sent to a company that manufactures chunks of the DNA containing the sequence. Finally, back in the laboratory, these short strands are joined together to make long sections of DNA.

Boeke's research has so far built one-third of the yeast genome and he hopes the rest will be constructed by the end of the year. But it will take longer to test the new DNA and fix problems, and subsequently combine the various chunks to complete the synthetic genome, he says.

At Harvard University, researchers Jeffery Way and Pamela Silver are developing harmless strains of salmonella DNA to be used as a vaccine against food poisoning that is caused by Salmonella, E. coli and Shigella.

To render the bacteria harmless when picking up DNA from other bacteria, requires altering the genome in 30,000 sites.

The only practical way to do that, Way says, is to synthesize it from scratch.

Whilst they said they were heartened to see that the leaders of GP-write have started discussions of ethical, legal and social issues, the idea of making a human genome is still a sensitive one.

Attorney Nancy J. Kelley, who organised the secret meeting in May and helped found the New York Genome Center, also mentioned that ethical concerns were only given a passing mention.

You can only introduce the concepts. You cant really discuss them or raise a debate about them in the paper," she added.

Zoloth and Endy were against the pursuit of the synthesis of human DNA, but the project has already begun taking shape with support from the Centre of Excellence for Engineering Biology, which will oversee the project and California-based software company Autodesk, which has committed USD250,000.

But more work still has to be done to convince the scientific community and the team recognises that.

The notion that we could actually write a human genome is simultaneously thrilling to some and not so thrilling to others, Boeke said. So we recognize this is going to take a lot of discussion. MIMS

Read more:Are we over-propagandising genetic research?FDA approves sale of genetic tests for disease riskHuman knockouts: A way to decipher why some drugs work, while others failSources:https://www.statnews.com/2016/06/02/project-human-genome-synthesis/https://www.statnews.com/2017/07/26/scientists-build-dna-scratch-alter-lifes-blueprint/http://www.cnbc.com/2017/05/02/synthetic-dna-scientist-says-it-could-be-inside-humans-within-5-years.html

See original here:
"Rewriting" yeast genomes: Paving the way to create human DNA from scratch - MIMS General News (Hong Kong) (registration) (blog)

Read More...

Rheumatoid Arthritis Safety Spotlight Widens – Seeking Alpha

August 1st, 2017 7:49 pm

Gaining market share in rheumatoid arthritis has been looking ever more difficult because of new entries and looming biosimilar competition, and now a spotlight on safety has only added to the uncertainty.

The US FDA has cited specific cardiovascular safety issues with two of the current wave of rheumatoid arthritis agents, Lilly's (NYSE:LLY) Olumiant and Johnson & Johnson's (NYSE:JNJ) Plivensia, the former of which might need to conduct a new clinical trial to rule out risk. The eligible population for these agents numbers in the millions and has several existing choices, so regulators seem to be taking a more assertive approach on the safety profile of follow-on products.

Briefing documents released yesterday before an FDA advisory committee meeting on Plivensia, whose active ingredient is sirukumab, revealed that the staff wants its expert consultants to consider an imbalance in deaths, major cardiovascular events like heart attacks and strokes, and cancer in its clinical program. This comes a week after Lilly revealed that Olumiant had been knocked back because the FDA wants to analyse an imbalance in thromboembolic events in its trials more closely.

In Plivensia's trials investigators said 34 of 35 deaths were in patients receiving the injection, and 13 of the 34 were from major adverse cardiovascular events. Like other IL-6 inhibitors, the project raises low-density lipoproteins. Overall, there was an imbalance in overall cardiovascular events in the Plivensia 50mg group, for which J&J is seeking approval, versus placebo, the FDA concluded.

Last week, Lilly reported that the FDA had cited five cases of deep-vein thrombosis or pulmonary embolism in its complete response letter denying approval of Olumiant.

In both cases, the regulator's caution might have been motivated by experiences with products in the same classes already on the market. The FDA's adverse events monitoring has identified 18 primary cases of pulmonary embolism with Olumiant's Jak inhibitor predecessor Xeljanz, according to FAERS data compiled by Advera Health. Actemra, which is an IL-6-inhibiting antibody like Plivensia, has reported 21 (Olumiant clot signal echoes Xeljanz experience, July 26. 2017).

As Lilly did last week with Olumiant, J&J says it is confident that the benefit of Plivensia outweighs the risk.

The end of unmet needs

The allure of the $25bn rheumatoid arthritis space is strong, but as biosimilars of established products prepare to enter it is becoming harder to argue that there is an unmet medical need in the disease and in associated autoimmune disorders.

The RA population numbers nearly 2 million in the US, and if all the indications for which the market leader, Humira, is prescribed excluding psoriasis are considered, the eligible population rises to more than 4 million. Thus the FDA might be growing more cautious about approving agents that could result in a significant number of complications and deaths.

Moreover, biosimilars are on their way - so far, the US FDA has approved copycats of Abbvie's (NYSE:ABBV) Humira and Roche's (OTCQX:RHHBY) Enbrel, and Pfizer (NYSE:PFE) has launched the Remicade biosimilar Inflectra. Their entry means that the US market for rheumatoid arthritis agents is not expected to expand measurably in sales terms from $14bn this year, and new entrants will not want to test a fiercely competitive market at a safety disadvantage.

Forecasts for Olumiant have shrunk to less than $1bn in 2022 since Lilly received the bad news from the FDA, and Plivensia US sales forecasts remain modest at $638m in 2022; Actemra will top out at about $1bn in 2021. Taken together the IL-6s are dwarfed in autoimmune disease by the anti-TNF class of Humira, Enbrel and Remicade.

In a saturated market it looks tough for Plivensia to meet these forecasts even with a clean label. A cardiovascular warning, should the FDA require one, will make it even more difficult.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

View original post here:
Rheumatoid Arthritis Safety Spotlight Widens - Seeking Alpha

Read More...

Arthritis symptoms: Painkillers could be hiding THIS serious condition from doctors – Express.co.uk

August 1st, 2017 7:49 pm

Axial spondyloarthritis is a form of arthritis, and it is estimated around 700,000 people in the UK live daily with inflammatory back pain.

A study funded by Arthritis Research UK, aims to see how big a role patients medication plays in slowing down diagnosis of axial spondyloarthritis.

Most manage the pain with anti-inflammatory drugs such as ibuprofen or other slightly stronger variants while they wait to have the condition formally diagnosed by a rheumatologist.

Axial spondyloarthritis is an inflammatory condition affecting the spine and joints in the pelvis and in extreme cases can lead to parts of the spine fusing together.

It is diagnosed using MRI scans after which it cannot be cured but can be managed with special anti-inflammatory medication.

Researchers from the University of Aberdeen suspect that some people who undergo an MRI scan receive a negative diagnosis for axial spondyloarthritis because the Ibuprofen-like drugs they are taking sufficiently reduce the inflammation and hide the symptoms.

Early diagnosis is key to preventing axial spondyloarthritis getting worse but typically it can take between eight to 11 years to be properly identified.

Dr Gareth Jones, a musculoskeletal pain and spondyloarthritis expert and lead author on the study said: The fact that it can take up to 11 years to get a formal diagnosis of axial spondyloarthritis is obviously a concern.

There are good drugs to help people manage the condition but they are only available to people who get a correct diagnosis.

We suspect some people who are getting scanned for the condition, who still have anti-inflammatory drugs like ibuprofen in their system, are scanning negative for axial spondyloarthritis because the drugs are masking the true extent of the inflammation.

This study aims to show whether or not these drugs do mask the condition, and what proportion of sufferers could potentially be affected.

If we see that the painkillers are indeed leading to negative diagnoses then it will lend support to the argument that anyone receiving an MRI scan for back pain should halt their regular anti-inflammatory medication for a week or so prior to the scan.

This study will give an indication as to what proportion of axial spondyloarthritis are misdiagnosed as a result of the anti-inflammatory drugs.

Two hundred and fifty patients with the condition will be recruited to the study from around 20 different centres.

They will stop taking their regular anti-inflammatory drugs (Ibuprofen, etc) for a week and then given an MRI scan. They will then start taking the drugs again for six weeks before receiving a second MRI scan.

The researchers will then compare the proportion of people who scanned positive for axial spondyloarthritis with those who scanned negative for the condition once they are back on them.

Stephen Simpson, director of research and programmes at Arthritis Research UK, added: Axial spondyloarthritis is an incredibly painful condition, which can have a devastating impact on a persons everyday life.

For example, those with ankylosing spondylitis are three times more likely to stop work than the general population.

This new research will prompt conversations around whether patients should be asked to refrain from taking non-steroidal anti-inflammatory drugs immediately prior to an MRI scan and to rely, instead, on other pain relief during this specific period.

This research could lead to earlier diagnosis for people living with the condition, leading to earlier commencement of appropriate treatment and improved outcome.

Read more here:
Arthritis symptoms: Painkillers could be hiding THIS serious condition from doctors - Express.co.uk

Read More...

Arthritis symptoms could be eased with THIS therapy: New hope for sufferers – Express.co.uk

August 1st, 2017 7:49 pm

According to Arthritis Research UK, over eight million people in the UK suffer from osteoarthritis - a condition perceived as only a disorder that affects the elderly.

A new walking programme for adults with arthritis and musculoskeletal conditions, made popular in the US, is to be trialled in the UK for the first time.

Walk With Ease was developed by the Arthritis Foundation in the US and has been shown to reduce arthritis-related symptoms such as pain, stiffness and fatigue, as well as improve strength, balance and walking pace.

The study is being funded as a joint working programme between ARUK and Pfizer Ltd, in partnership with the Chief Scientists Office of the Scottish Government and led by Dr Kathryn R Martin.

Dr Martin said: Walk With Ease has proven extremely successful in the US at reducing pain, stiffness and fatigue while improving physical functioning for those who have taken part.

We want to see if the ethos and logistics of the programme can be implemented in the UK.

This study will examine whether or not individuals with arthritis and musculoskeletal conditions living in the UK are willing to take part in such a programme and whether or not they feel it benefits them.

We are starting with Aberdeen and hope that if successful it can be rolled out across the UK.

This comes after Ruby James, 55, told Express.co.uk that exercise was the best way to reduce the symptoms of osteoarthritis.

Ruby said: I make sure I keep moving and exercising, as I always have, as I really feel that this makes my osteoarthritis more manageable.

Letters are currently being sent out from GP practices to potential participants for the six-week community-based programme.

Following an initial assessment of their mobility, participants will either receive the walking programme or a booklet outlining physical activity programmes in Aberdeen.

Those who receive the walking programme will be given a guidebook and the option to either walk with a group or on their own.

All participants will be re-assessed after six weeks and be posted a questionnaire three months later to see what effects the programme has had on them.

Some participants will also be asked to take part in an interview to discuss their experiences of being in the study.

Dr Natalie Carter, head of research liaison and evaluation at Arthritis Research UK, said: At Arthritis Research UK, we know that exercise, such as walking, can help to both prevent and improve the symptoms of arthritis.

Much more needs to be done to help support people with joint pain to stay active.

That is why our charity funds a number of studies focusing on exercise and movement, and we are pleased to be supporting the Walk With Ease study.

View original post here:
Arthritis symptoms could be eased with THIS therapy: New hope for sufferers - Express.co.uk

Read More...

Understanding arthritis – Michigan State University Extension

August 1st, 2017 7:49 pm

23 percent of all adults are affected by arthritis in the United States, and the symptoms associated with this chronic disease cost our country over 81 million dollars in annual medical bills.

Posted on July 31, 2017 by Kris Swartzendruber, Michigan State University Extension

Arthritis is a disease that affects over 54 million people in the United States. According to the Centers for Disease Control and Prevention, arthritis is the leading cause of disability, with related medical expenses reaching $81 billion. It is estimated that by the year 2040 nearly 26 percent of all adults (over 78 million people) will have arthritis.

The CDC also reports that arthritis significantly limits the workforce in this country. Because 60 percent of adults with this disease are of working age (18-64 years), arthritis can limit the type of work they do, and in many cases, keep them from working at all.

What is Arthritis?

Arthritis is chronic pain condition that is most commonly caused by inflammation of the tissue lining the joints (joints are located where two or more bones meet, such as elbows and knees). Symptoms vary, but the most common are pain, aching, swelling and stiffness.

There are over 100 diseases and conditions that are referred to as arthritis, but the most prevalent is osteoarthritis. Osteoarthritis usually occurs in older adults, affecting their fingers, knees and hips and can be a result of a previous injury to a joint. Other well-known types of arthritis include gout, lupus and rheumatoid arthritis. Rheumatoid arthritis and lupus occur when the bodys defense system doesnt work properly, and overtime, can affect multiple organs and cause widespread symptoms.

Who is affected by arthritis?

Arthritis does not discriminateit affects people of every age, race and gender. However, statistics show that the risk of arthritis increases with age and is more common among women than men. The CDC reports that arthritis commonly occurs with other chronic diseases with half of adults with heart disease or diabetes, and one-third of people who are obese, having arthritis. When a person has to deal with arthritis, along with another chronic health condition, it can negatively affect their quality of life and make it more difficult for doctors to treat and manage their diseases.

What can I do if I have arthritis?

The good news is, there are several ways to treat and reduce the symptoms associated with arthritis. If you, or someone you care for, is affected by arthritis, Michigan State University Extension recommends that you first talk with a doctor. The National Institute of Arthritis and Musculoskeletal and Skin Diseases says that only a doctor can diagnose and provide you with the best form of treatment associated with diabetes.

In addition to working with a healthcare provider, there are several things a person can do on their own to help control their pain and maintain their health. My next three news articles will focus on these arthritis self-management tools:

MSU Extension also provides high-quality and affordable education and resources related to the prevention and management of chronic disease.

This article was published by Michigan State University Extension. For more information, visit http://www.msue.msu.edu. To have a digest of information delivered straight to your email inbox, visit http://www.msue.msu.edu/newsletters. To contact an expert in your area, visit http://expert.msue.msu.edu, or call 888-MSUE4MI (888-678-3464).

Original post:
Understanding arthritis - Michigan State University Extension

Read More...

Pharmalittle: FDA staff cautious on J&J arthritis drug; Kite seeks EU nod for CAR-T drug – STAT

August 1st, 2017 7:49 pm

H

ello, everyone, and how are you today? We are doing just fine, thank you, especially now that the Pharmalot campus has quieted down. Both Mrs. Pharmalot and the shortest person have left for their respective destinations, and the official mascots are snoozing contentedly in their usual spots. This leaves us to forage for interesting items for you. On that note, here are some tidbits. Have a wonderful day and do let us know about juicy developments

An experimental rheumatoid arthritis drug from Johnson & Johnson was linked to more deaths than a placebo, Food and Drug Administration staff reviewers wrote in an advance of a Wednesday expert panel meeting, Reuters writes. Other possiblesafety issues were similar to other drugs in the class, but the trend of increased overall mortality seems unique for this medicine, they wrote.The most common causes of death were major heart problems, infection, and malignancies.

This is a STAT Plus article and is only available to STAT Plus subscribers.To read the full story, subscribe to STAT Plus or log in to your account.Good news: your first 30 days are on us.

Pharmalot Columnist, Senior Writer

Ed covers the pharmaceutical industry.

Read more here:
Pharmalittle: FDA staff cautious on J&J arthritis drug; Kite seeks EU nod for CAR-T drug - STAT

Read More...

MSK conditions must be central to multimorbidity plans, says Arthritis Research UK – Chartered Society of Physiotherapy

August 1st, 2017 7:49 pm

Arthritis Research UK says by 2018 there will be 2.9m people living with multimorbidity

The call is made in a report by Arthritis Research UK exploring why MSK conditions must be included in future plans to address multimorbidity.

Arthritis Research UK says that NHS England should ensure that metrics and tools used in multimorbidity programmes include monitoring and measuring of pain and its impact on functional abilities and capability to manage.

Research funders, such as the National Institute for Health Research, should work with partners to ensure there is a flourishing research agenda covering multimorbidity, which includes common conditions such as MSK conditions.

Good MSK health underpins living well and independently with multimorbidity, but MSK conditions are too often overlooked, the charity says.

Meanwhile MSK conditions affect around 10 million people across the UK, and are often found in people with other long-term conditions.

The report reveals that among people over 45 years with a major long-term condition, more than 30 per cent also have arthritis. By 65, almost half of people with a heart, lung or mental health problem also have arthritis.

Conversely, 80 per cent of people with osteoarthritis have at least one other long-term condition such as hypertension, cardiovascular disease or depression.

Arthritis Research says it is essential to recognise the interaction between MSK conditions and other health problems.

Any long-term condition is associated with a drop in quality of life, but when arthritis or back pain is part of multimorbidity, the drop is greater. The pain and functional limitations of arthritis make it harder to cope when living with other long-term conditions.

Professor Peter Kay, NHS Englands national clinical director of MSK Services said: We must work across systems to ensure we have the appropriate data collected and available to understand the numbers and requirements of people living with multiple long-term conditions.

View original post here:
MSK conditions must be central to multimorbidity plans, says Arthritis Research UK - Chartered Society of Physiotherapy

Read More...

Arthritis charities set to merge later this year – Charity Today News

August 1st, 2017 7:49 pm

ARTHRITIS Care and Arthritis Research UK have announced that they are to merge to help over 10 million people living with arthritis in the UK.

The charities say that they began discussions at the turn of the year and that due diligence is now underway.

In a joint statement Dr Liam OToole, chief executive of Arthritis Research UK and Judi Rhys, chief executive of Arthritis Care, said Currently there are too many people living with the pain, fatigue and isolation caused by arthritis. The two charities are doing great work to address their needs, and we know we can have a greater impact on peoples lives by creating one organisation.

The aspirations of people with arthritis are changing and it is vital that we continue to meet their expectations. We can stand together with one louder voice to change attitudes and press for change. We can transform our care, support and information services so that many more people can build their knowledge, skills and resilience to live well with arthritis. We will continue our fight to find better treatments and even a cure and well now be able to offer our supporters, members, volunteers, branches and groups the opportunity to join patient-focussed clinical trials and influence the research agenda.We believe that this is a truly exciting step.

The charities hope to come together in a single organisation in October this year.

Follow this link:
Arthritis charities set to merge later this year - Charity Today News

Read More...

More Americans Than Ever Say Polygamy Is Morally Acceptable – HuffPost

August 1st, 2017 7:49 pm

The practice of polygamy, or having more than one spouse at the same time, is illegal in all 50 states. But the percentage of Americans who say the practice is morally acceptable reached an all-time high this year, according to a recent Gallup poll.

Gallup has measured American attitudes toward a number of social issues and behaviors, such as divorce, same-sex relations, and stem cell research, since 2001. In that time, the percentage of Americans who find polygamy to be morally acceptable has risen from seven to 17 percent.

Of all the issues and behaviors Gallup asked about, polygamy is among those to gain the most ground on moral acceptance since 2001, after same-sex relations, having a baby out of wedlock, sex between an unmarried man and woman and divorce.

Gallup initially attributed a 2011 bump in Americans acceptance of polygamy to a change in the wording of the question.Before 2011, Gallup defined polygamy as being when a husband has more than one wife at the same time.

But polygamy is actually a gender-neutral term that refers to the practice of having more than one spouse at a time. The majority of polygamous societies around the globe practice polygyny, when a man marries more than one woman. Another form of polygamy, called polyandry, refers to when a woman has more than one husband.

In 2011, Gallup changed its definition to reflect the terms gender-neutrality, identifying polygamy as when a married person has more than one spouse at the same time.

The change in wording coincided with a bump in the percentage of Americans who found polygamy morally acceptable but the continued rise likely has little to do with semantics, Gallup analyst Andrew Dugan wrote in a recent article.

The growing moral acceptance of polygamy may be part of a broaderleftward shifton moral issues, Dugan wrote, as well as increased depictions of the marital practice in popular media.

In the wake of the Supreme Courts 2015 ruling legalizing same sex marriage in all 50 states, scholar and cultural commentator Fredrik deBoer argued in article on Politico that polygamy would be the next horizon of social liberalism.DeBoer seemed to echo in positive terms what many social conservatives ominously warned: that legal changes to so-called traditional marriage could lead to anything even group marriage.

Within the U.S., though, polygamy tends to be most common among highly religious groups, including conservative Muslim immigrants from parts of Africa and Asia and the insular, isolated Fundamentalist Church of Jesus Christ of Latter-Day Saints.

The latter, a religious sect that broke off from the Church of Jesus Christ of Latter-Day Saints or Mormon Church in the 1930s, has been associated with the sexual abuse of children. Its leader,Warren Jeffs, was sentenced to life in prison in 2011 for having sex with underage girls.

In addition to several high-profile cases of child abuse linked to polygamous groups, plural marriage has also been linked to genetic disorders, child development problems for the offspring of such unions, a number of social issues including rape and substance abuse in societies where theres a disproportionate number of unmarried men as a result of polygyny, and even an increased risk of heart disease for polygamous men.

Even with polygamys problems and traditionally religious associations, Gallup found that acceptance of the practice is highest among non-religious Americans. Thirty-two percent of Americans who arent affiliated with any religion or who arent religious at all said polygamy ismorally acceptable.

Americans who identify as Christian were more likely than the overall same average to find the practice to be morally intolerable, even given the Biblical precedent for polygamy.

The Morning Email

Wake up to the day's most important news.

See the original post here:
More Americans Than Ever Say Polygamy Is Morally Acceptable - HuffPost

Read More...

Charlie Gard Dies, Leaving a Legacy of Thorny Ethics Questions – New York Times

August 1st, 2017 7:49 pm

Our final wish

They lost their fight. On Thursday, Ms. Yates, who works as a caregiver, said in statement that the hospital had denied us our final wish.

Most people wont ever have to go through what we have been through, she said. Weve had no control over our sons life and no control over our sons death.

But the doctors treating Charlie at Great Ormond Street Hospital in central London countered that the risk of an unplanned and chaotic end to Charlies life at home was unthinkable. For months, the hospital had argued that he had irreversible brain damage, that the life support should be removed and that he should be allowed the right to die with dignity.

We deeply regret that profound and heartfelt differences between Charlies doctors and his parents have played out in court over such a protracted period, the hospital said in a statement. We will never do anything that could cause our patients unnecessary and prolonged suffering.

The case laid bare several issues, among them: Should parents or doctors or the courts have the final say in irreconcilable disputes over the treatment of sick children? And at what point should the limits of medicine be recognized and the parents of an infant be compelled to let go?

Biomedical ethicists said the case offered a cautionary tale of how a legal battle, scrutiny by the global news media and intractable differences between parents and doctors can spiral out of control in the social media age. Both the hospital and the parents in the Gard case dug in, their arguments playing out on Facebook and Twitter and capturing the attention of world figures including President Trump and Pope Francis.

The pope posted a message on his personal Twitter account shortly after news broke of the infants death. I entrust little Charlie to the Father and pray for his parents and all those who loved him, the tweet said.

Dr. Robert D. Truog, a physician at the pediatric intensive-care unit at Boston Childrens Hospital and the director of the Center for Bioethics at Harvard Medical School, said that Charlies parents were like parents all over the world they were willing to do absolutely anything to save the life of their child.

He added: They were the victims, not the cause, of this tragic situation.

The parents raw emotions played out in the courtroom, where Ms. Yates broke down in tears of frustration, at one point shouting, What if it was your child? before fleeing the room. At another moment, Mr. Gard, a mailroom worker, cried out, Evil after a hospital lawyer spoke.

On several occasions, both parents stormed out of the courtroom. Some of the lawyers and journalists covering the case were reduced to tears.

The case went through several courts, including Britains Supreme Court and the European Court of Human Rights, which backed the hospitals views, in part because experts said Charlie could be suffering. His parents insisted he was not.

Some American conservatives seized on the case as a warning of the pitfalls of socialized medicine and the abrogation of parental rights, even as the High Court judge presiding over the case, Nicholas Francis, countered that to make a scapegoat out of Britains National Health Service was nonsensical.

In most cases, medical experts say, doctors decide when to remove life support from an incurably ill child, in consultation with parents, and these cases rarely wind up in court. But in Britain, the courts are the final arbiter when irreconcilable disputes arise.

Charlie also became a powerful symbol for anti-abortion groups the world over. Protesters picketed outside Great Ormond Street Hospital, and Judge Francis denounced death threats against hospital staff members.

The case also spurred questions about the wisdom of offering parents the hope of experimental treatment when faced with an incurable disease. That debate took center stage after Dr. Michio Hirano, a neurologist at Columbia University Medical Center in New York, offered Charlies parents a ray of hope that an experimental treatment known as nucleoside therapy could improve Charlies condition.

The treatment had been tested on mice and on 18 people with a mutation in a gene known as TK2. But it had never been tried on someone with Charlies particularly debilitating form of mitochondrial DNA depletion syndrome, which is caused by a different genetic mutation.

During an often-acrimonious and emotional High Court hearing this month, Charlies parents argued that he should be allowed to receive the experimental treatment. But lawyers for Great Ormond Street Hospital countered that Dr. Hirano had held out hope without even examining the child or reviewing his full medical charts.

(Dr. Hirano said in a statement he had been contacted by the parents and agreed to speak with Charlies doctors to determine whether the experimental therapy he was developing could help improve the childs condition).

When Dr. Hirano traveled to London this month to examine Charlie, about six months after he had first been invited, a series of scans showed that the boy had suffered muscular atrophy, that the damage was irreversible and that treatment would be futile.

Ms. Yates criticized the hospital, saying it had dragged its feet about the treatment until it was too late.

The hospital consistently stood by its contention that treatment would have been useless and that Charlie had irreversible brain damage.

If Charlie has had a relationship with the world around him since his best interests were determined, it has been one of suffering, it said in a statement.

Dominic Wilkinson, a neonatologist and professor of medical ethics at Oxford University, said the case offered a tragic lesson about the risks of doctors offering uncertain hope to desperate parents. At the same time, he said, the case underscored the importance of mediation during a dispute about treatment, noting that the communication breakdown in the Gard case had all the attributes of a messy divorce.

To let a child go is incredibly difficult, but it is also incredibly important, he said. It is heartbreaking, but we have to know when to say enough is enough.

Dr. Truog of Harvard Medical School said the parents legal battle had tapped into the health care debate in the United States, and was being seized upon by some to affirm a money-driven system in which patients who have the means can pursue experimental treatments, even if the chances of success are slim. But he said experimental treatments must be weighed against the benefits for society as a whole.

In the United States, no one can demand nonbeneficial treatments simply by claiming they are paying out of pocket, he wrote in a recent article on the Gard case in The Journal of the American Medical Association.

It would be extremely rare for a hospital in the United States to admit patients for the exclusive purpose of receiving homeopathic therapy or unproven stem cell infusions, he wrote, regardless of how much the patient paid.

The parents now face coming to terms with Charlies death. Addressing the court this past week, Ms. Yates acknowledged that this would not be easy.

We are struggling to find any comfort or peace with all this, she said. But one thing that does give us the slightest bit of comfort is that we truly believe that Charlie may have been too special for this cruel world.

Go here to read the rest:
Charlie Gard Dies, Leaving a Legacy of Thorny Ethics Questions - New York Times

Read More...

India needs biannual amendment to Stem Cell Rules, Section 8 of Rules controversial: Dr Totey – pharmabiz.com

August 1st, 2017 7:49 pm

India needs stem cell guidelines which can be amended biannually, said Dr Satish Totey, founder, chairman & managing director, Aureostem Research Pvt Ltd.

There cannot be a permanent set of guidelines. Every year we should make new draft guideline and seek public opinion. This must be discontinued immediately since valuable time and money are invested in the same. Instead it should be amended biannually, Totey told Pharmabiz.

Although the recent guidelines are comprehensive and may ensure patients get reliable and safe stem cell products in India in near future, yet the controversial section of this is Section 8. The section defines level of stem cell manipulation as minimum and major which is absolutely unnecessary and gives clear escape route to push unapproved stem cell for therapy by the clinicians, he said.

Desperate patients do not understand this terminology and often misled by the clinicians. For instance adipose derived stromal vascular fraction (AD-SVF) or bone marrow derived mononuclear cells (BM-MNC) which is minimal manipulated cells are being extensively used by the clinicians and giving impression to the patients that it do not require any clinical trials.

Now several clinicians use minimal manipulated cells for transplanting in retinas or in the brain without knowing its safety and efficacy. Much of what is being injected through minimum manipulated cells are not even stem cells. Moreover, one that come from fat or bone marrow are not capable of living in the human body for more than a day. There are several reports that patients become blind after such transplants, explained Dr Totey.

Another aspect which was totally ignored in the guideline is stem cell devices. Several clinicians use stem cell devices routinely in India which has limited approval from US FDA even for specific clinical conditions in the US. Therefore, such devices cannot be used in India. But clinicians are seen to mislead patients and giving impression that they have US FDA approval for stem cell therapy. This is a most dangerous procedure where, clinician can treat any condition without even having clinical speciality. For example, cosmetologists are now treating neurological or cardiac conditions. One of the key issues are oversight. But in these cases it is not just about desperate patients losing money but the genuine and tangible harms being done in the absence of oversight, he said.

Real progress in stem cell research and the development of cellular pharmaceuticals is not going to result from clinics making dramatic marketing claims. True progress requires extensive basic and pre-clinical research. It should be backed by carefully designed and properly conducted randomized clinical trials to ensure high-quality safety and efficacy data is generated.

Conducting such research in an ethical, scientific, and legal manner is difficult, costly, time-consuming, but necessary. More than 300 stem cell clinics that are operating in India are making dramatic advertising claims about stem cell treatments, but in most cases they have no evidence to support their hard-sell marketing, said Dr Totey.

See the article here:
India needs biannual amendment to Stem Cell Rules, Section 8 of Rules controversial: Dr Totey - pharmabiz.com

Read More...

Regenerative Medicine Market in the US to Grow at a CAGR of 23.5 … – Business Wire (press release)

August 1st, 2017 7:48 pm

DUBLIN--(BUSINESS WIRE)--The "Regenerative Medicine Market in the US 2017-2021" report has been added to Research and Markets' offering.

The Regenerative Medicine Market in the US to grow at a CAGR of 23.53% during the period 2017-2021.

The report, Regenerative Medicine Market in the US 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is the increasing strategic alliances. Major vendors are entering into strategic alliances with other vendors for drug development and manufacturing. The trend is anticipated during the forecast period. Leading vendors in the market are undertaking M&A to strengthen their global position and to improve their commercial capabilities. Through increasing strategic alliances, many companies are receiving upfront and royalty payment, which encourages many small companies to involve into R&D and develop novel regenerative medicine products.

According to the report, one of the major drivers for this market is CVD and diabetes in young adult and aging population. CVD is a common disease in the older population; however, it is growing high among young adults owing to lifestyle and over-indulgement in junk foods. A combined study conducted by the Department of Clinical and Experimental Medicine, University of Florence; Department of Health Sciences, University of Milano-Bicocca; and Department of Cardiology, S. Luca Hospital, IRCCS Istituto Auxologico Italiano, Italy in 2015, found that uncontrolled blood pressure increases the risk of CVDs such as stroke and heart attack.

Key vendors

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Pipeline portfolio

PART 07: Market segmentation by product

PART 08: Market segmentation by application

PART 09: Market segmentation by end-user

PART 10: Decision framework

PART 11: Drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

PART 14: Key vendor analysis

For more information about this report visit https://www.researchandmarkets.com/research/8dnt7z/regenerative

See the original post here:
Regenerative Medicine Market in the US to Grow at a CAGR of 23.5 ... - Business Wire (press release)

Read More...

Stem Cell Therapy can provide a surgery-free solution to knee and shoulder issues – Colorado Springs Gazette

August 1st, 2017 2:44 am

Springs Integrated Health offers leading-edge, all-natural medical care. The center provides services intended to get to the root of patient issues and deliver real, lasting results in the simplest, most effective way. Instead of covering up symptoms with medications, the clinic breaks down health into obtainable goals that can optimize the wellness of each and every patient. Services include chiropractic, hormone lab testing, physical rehabilitation, Supartz therapy, trigger point therapy, FAR infrared sauna, stem cell therapy and more.

There was a time when stem cell therapy was out of reach for most people, but it has become increasingly accessible in recent years; and a go-to solution for a range of physiological complications. Stem cells are blank cells in the body that can become any tissue, whether that be knee tissue, bone tissue, cartilage, organ tissue stem cells can become whatever they are closest and nearest to, said Tiffany Graham, DC of Springs Integrated Health. So when you inject them into a joint thats damaged the body is always healing itself anyway it can create new tissue where there has been damage.

Stem cell therapy has been used for decades in Europe, and in the United States has been used by Peyton Manning, Tiger Woods, and many NFL players and other professional athletes. Although stem cells were initially reserved for the ultra wealthy, they have since become both affordable and accessible; and many patients are opting for them over lengthy and expensive knee and shoulder surgeries. One in 400 total knee replacements result in fatal infection, and those that do not end up in infection still prove to have an extensive recovery time. Stem cell therapy is safe and quick, and people can feel results in as little as one week. Further, the company Springs Integrated Health utilizes for stem cells has given more than 50,000 injections with zero side effects and zero adverse reactions.

There are two different types of stem cells. The first is adult stem cells, where patients take their own bone marrow, fat or blood; spin it down; and re-inject into the joints. Thats not what is used at Springs Integrated Health, because its a long procedure that can be very painful and expensive. The second is amniotic stem cells, which are from donated placental tissue. This tissue comes from mothers who have planned c-sections, and who have elected to donate their placenta to science. The stem cells have been thoroughly tested and are clear of all antigens, so there is no risk for rejection or infection. The stem cells used at Springs Integrated Health are 100 percent ethically-sourced, and are not embryonic stem cells, which come from aborted fetal tissue, said Graham.

Rick Paine is a beaming example of the efficacy of stem cell therapy. He is an avid runner and hiker, and coached swimming at the University of Nebraska for 17 years. He was also an Olympic Head Coach in Australia in 2000. Eight years ago, he wore his left knee out and had to get a knee replacement, and it took two to three years to recover. About two years ago, his right knee was becoming worn out, and he did not want to go through the another knee surgery, because it was a very unpleasant experience for him. He was seeing an active release therapist who was helping, but he still had trouble with downhill on hikes, walking on the golf course and doing the everyday activities that make him happy.

Paine had been seeing Dr. Graham for about a year and a half before deciding to commence with stem cell therapy for his torn medial meniscus on the right knee in November 2016. At first I was skeptical, but I thought, lets give it a shot, Paine said. The procedure was quick and pretty painless, and it only took about a month after the injection for my knee to feel really good. He cautions that although the knee may feel great in a month or less, its essential to still take it easy, and give the tissue time to grow before becoming physically active.

Before I got stem cells, I couldnt squat to pick up a ball on the golf course but since getting the stem cells I can definitely do that. Im 65 years old, and a surgery would have taken me out of hiking for two to three years, but with this, it was only three months until I was hiking again, said Paine. We took X-rays a few months ago, and there has been significant improvement in my knee. I didnt expect to see that, I thought it was too good to be true, but Im living proof that stem cell therapy works.

Paine shared that now, eight months after his procedure, his knee still feels perfect. He admits that its not like having a brand new knee, but he has no issues whatsoever with downhill, uphill or bending down. I knew I wanted to do at least one more 14er, and didnt think it would be possible, but stem cells have definitely allowed me to do that. Paine is now gearing up for a 12 mile hike from Crested Butte to Aspen, a hike he couldnt have even considered before stem cells. I wish we had stem cells way back when, because it would have saved a lot of athletes careers.

To receive a complimentary consultation, or to attend an upcoming, free informational seminar at Springs Integrated Health, call 719-301-6649 or visit SpringsIntegratedHealth.com.

Springs Integrated Health is located at 1712 W. Uintah St., Colorado Springs. Hours are Monday, 10 a.m. to 12:30 p.m. and 3 to 6 p.m.; Tuesday, 3 to 6 p.m.; Wednesday, 10 a.m. to 12:30 p.m. and 3 to 6 p.m.; Thursday, 3 to 6 p.m.; and Friday 8 to 10 a.m.

See the article here:
Stem Cell Therapy can provide a surgery-free solution to knee and shoulder issues - Colorado Springs Gazette

Read More...

Regenerative Medicine – AABB

August 1st, 2017 2:44 am

Regenerative medicine may be defined as the process of replacing or "regenerating" human cells, tissues or organs to restore or establish normal function. This field holds the promise of regenerating damaged tissues and organs in the body by replacing damaged tissue or by stimulating the body's own repair mechanisms to heal tissues or organs. Regenerative medicine also may enable scientists to grow tissues and organs in the laboratory and safely implant them when the body is unable to heal itself. Current estimates indicate that approximately one in three Americans could potentially benefit from regenerative medicine.

Regenerative Medicine refers to a group of biomedical approaches to clinical therapies that may involve the use of stem cells. Examples include cell therapies (the injection of stem cells or progenitor cells); immunomodulation therapy (regeneration by biologically active molecules administered alone or as secretions by infused cells); and tissue engineering (transplantation of laboratory grown organs and tissues). While covering a broad range of applications, in practice the latter term is closely associated with applications that repair or replace portions of or whole tissues (i.e., bone, cartilage, blood vessels, bladder, skin). Often, the tissues involved require certain mechanical and structural properties for proper functioning. The term has also been applied to efforts to perform specific biochemical functions using cells within an artificially-created support system (e.g., artificial pancreas or liver).

Cord blood stem cells are being explored in several applications including Type 1 diabetes to determine if the cells can slow the loss of insulin production in children; cardiovascular repair to observe whether cells selectively migrate to injured cardiac tissue, improve function and blood flow at the site of injury and improve overall heart function; and central nervous system applications to assess whether cells migrate to the area of brain injury alleviating mobility related symptoms, and repair damaged brain tissue (such as that experienced with cerebral palsy). Cord blood stem cells likely will be an important resource as medicine advances toward harnessing the body's own cells for treatment. Because a person's own (autologous) stem cells can be infused back into that individual without being rejected by the body's immune system, autologous cord blood stem cells have become an increasingly important focus of regenerative medicine research.

Regenerative medicine has made its way into clinical practice with the use of materials that are able to assist in the healing process by releasing growth factors and cytokines back into the damaged tissue (e.g., (chronic) wound healing). As additional applications are researched, the fields of regenerative medicine and cellular therapies will continue to merge and expand, potentially treating many disease conditions and improving health for a variety of diseases and health conditions.

Read the original here:
Regenerative Medicine - AABB

Read More...

With New Biotech Institute, Manchester Aims to Be Hub for … – Nhpr – New Hampshire Public Radio

August 1st, 2017 2:44 am

Dean Kamen brought the world the Segway and helped to transform New Hampshire's Millyard from a hollowed-out manufacturing strip to a growing tech hub. Now, he's setting his sights on making Manchester a hub for a whole new field of medicine.

It sounds like the kind of stuff that at one time was relegated to science fiction. An organ, grown from scratch, to replace one at risk for renal failure. A new, fully functioning limb for a soldier who lost his to combat.

But that's exactly the vision at the heart of the Advanced Regenerative Manufacturing Institute, or BioFabUSA -- a multimillion-dollar partnership led by Kamen and the Department of Defenseto come up with new approaches to biotechnology.

ARMI (pronounced like "army") launched primarily to help soldiers, but Kamen sees wide-reaching potential for patients across the board.

"If you had a choice of, you could treat my end-stage renal failure by sending me to a dialysis center three days a week for the rest of my life, or you can cure it, by giving me a replacement organ, which would you prefer? And if you could prevent the problem in the first place, which would you prefer?" Kamen said at an ARMI launch event in Manchester on Friday. "So, ironically this is one of those rare places where thetechnologythat we're developing is one that is going to give you a betteroutcome, but it also lowers the cost."

Kamen nabbed a former top official at the FDA to get the institute up and running, and he said he's secured more than $200 million in funding -- in addition to the $80 million the Department of Defense put up to launch the effort.

"We told the Department of Defense within five years, we will have products that are being placed in or on people to cure conditions that are a result of what's going on in this place," Kamen said. "I'd like to think some of them are sooner than that, but that's our goal."

And the inventor's not the only one excited about it.

"I love it," said Gov. Chris Sununu, one of several local dignitaries on hand for the launch. "Look, anything I can do to attract more geeks to New Hampshire, being a former geek myself."

Sununu was joined at the launch event by Sens. Maggie Hassan and Jeanne Shaheen, former Gov. John Lynch, former Sen. Kelly Ayotte and a number of other top names in the state's political, business and tech scenes -- the takeaway being, policymakers are seeing this as a big deal, and a big get for the Granite State.

More here:
With New Biotech Institute, Manchester Aims to Be Hub for ... - Nhpr - New Hampshire Public Radio

Read More...

Regenerative medicine startup Rodeo Therapeutics raises $5.9M for … – GeekWire

August 1st, 2017 2:44 am

Dr. Sanford Markowitz, founder of Rodeo Therapeutics. (Case Western Reserve University Photo)

If you could write a medical wish-list of futuristic technologies, regenerating tissue would be pretty high up there. It could do things like treat a variety of inflammatory conditions and even help cancer patients regrow healthy cells.

A new Seattle-based biotech startup, Rodeo Therapeutics, is hoping its technology can make tissue regeneration a reality, and it has just raised a $5.9 million Series A round from Seattle-based biotech fund Accelerator Corporationto make it happen.

The general idea is simple: Rodeo is hoping to use small-molecule therapies a category most drugs fall into that stimulate the bodys natural regeneration process, like when a skinned knee heals.

Its first focus is to develop a treatmentfor inflammatory bowel disease and one that can help cancer patients cells grow quickly following stem cell transplants.

But those goals are just the beginning.

The ability to stimulate the bodys natural processes for tissue regeneration and repair has broad therapeutic potential in disease settings such as ulcerative colitis and in hemopoietic recovery following bone marrow transplantation,said Rodeo Therapeutics founder and cancer researcher Dr.Sanford Markowitz. Rodeo Therapeutics is focused on developing small-molecule therapies that stimulate these processes and enable new approaches to address serious medical conditions that today have a substantial unmet medical need.

The company is currently working on drugs that inhibit an enzyme called 15-PGDH, which has been shown to speed up regenerative processes.

The startup was founded by Markowitz and Dr. Stanton Gerson, researchers at Case Western University, along with Dr.Joseph Ready, a researcher at the University of Texas Southwestern Medical Center.

Its technology is based on their work. Markowitz is an expert in gastrointestinal cancers, where inflammation can cause serious problems; Dr. Gerson specializes in stem cell and genetic research along with gene therapies and cancer drug development; and Dr. Ready works in regenerative medicine and cancer, specifically synthetic and medicinal chemistry.

The startups corporate office is currently in Accelerator Corporations facilities in Seattle, with its founders in Dallas and Cleveland. Rodeos early operations will be overseen by Accelerator, and the funds CEO Thong Le is currently servingas Rodeos CEO.

Visit link:
Regenerative medicine startup Rodeo Therapeutics raises $5.9M for ... - GeekWire

Read More...

Page 957«..1020..956957958959..970980..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick